1-6 of 6
Vicky Makker
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer

Angela K. Green, Qin Zhou, Alexia Iasonos, William A. Zammarrelli, III, Britta Weigelt, Lora H. Ellenson, Rashmi Chhetri-Long, Pooja Shah, Jade Loh, Vania Hom, Pier Selenica, Joseph Erinjeri, Iva Petkovska, Sarat Chandarlapaty, Seth Cohen, Rachel Grisham, Jason Konner, Maria M. Rubinstein, William Tew, Tiffany Troso-Sandoval, Carol Aghajanian, Vicky Makker
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF9.
https://doi.org/10.1158/1078-0432.CCR-24-1999
Published: 10 December 2024
View article titled, A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer
Open the PDF for A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract AP27: A PHASE 2 STUDY OF TPIV200/HUFR-1 (A MULTI-EPITOPE FOLATE RECEPTOR ALPHA VACCINE) IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER

Dmitriy Zamarin, Oladapo Yeku, Rosin E. O'Cearbhaill, Karen A. Cadoo, Jacqueline Gallagher, Sara Kravetz, Autumn McDonnell, Tiffany Troso-Sandoval, Paul Sabbatini, Stuart Lichtman, William Tew, Vicky Makker, Rachel N. Grisham, David M. Hyman, Carol Aghajanian, Jason Konner
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22_Supplement): AP27.
https://doi.org/10.1158/1557-3265.OVCASYMP18-AP27
Published: 15 November 2019
View article titled, Abstract AP27: A PHASE 2 STUDY OF TPIV200/HUFR-1 (A MULTI-EPITOPE FOLATE RECEPTOR ALPHA VACCINE) IN COMBINATION WITH DURVALUMAB IN PATIENTS WITH PLATINUM RESISTANT OVARIAN CANCER
Journal Articles

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

Jessica J. Tao, Nicholas A. Cangemi, Vicky Makker, Karen A. Cadoo, Joyce F. Liu, Drew W. Rasco, Willis H. Navarro, Christopher M. Haqq, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5458–5465.
https://doi.org/10.1158/1078-0432.CCR-19-1065
Published: 13 September 2019
View article titled, First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer

Tara E. Soumerai, Mark T.A. Donoghue, Chaitanya Bandlamudi, Preethi Srinivasan, Matthew T. Chang, Dmitriy Zamarin, Karen A. Cadoo, Rachel N. Grisham, Roisin E. O'Cearbhaill, William P. Tew, Jason A. Konner, Martee L. Hensley, Vicky Makker, Paul Sabbatini, David R. Spriggs, Tiffany A. Troso-Sandoval, Alexandra Snyder Charen, Claire Friedman, Mila Gorsky, Sarah J. Schweber, Sumit Middha, Rajmohan Murali, Sarah Chiang, Kay J. Park, Robert A. Soslow, Marc Ladanyi, Bob T. Li, Jennifer Mueller, Britta Weigelt, Ahmet Zehir, Michael F. Berger, Nadeem R. Abu-Rustum, Carol Aghajanian, Deborah F. DeLair, David B. Solit, Barry S. Taylor, David M. Hyman
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (23): 5939–5947.
https://doi.org/10.1158/1078-0432.CCR-18-0412
Published: 03 December 2018
View article titled, Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Open the PDF for Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer in another window
Includes: Supplementary data
Journal Articles

Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders

Rachel N. Grisham, Kathleen N. Moore, Michael S. Gordon, Wael Harb, Gwendolyn Cody, Darragh F. Halpenny, Vicky Makker, Carol A. Aghajanian
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (22): 5525–5533.
https://doi.org/10.1158/1078-0432.CCR-18-0494
Published: 15 November 2018
View article titled, Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders
Open the PDF for Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders in another window
Includes: Supplementary data
Journal Articles

Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors

David M. Hyman, Naiyer Rizvi, Ronald Natale, Deborah K. Armstrong, Michael Birrer, Lawrence Recht, Efrat Dotan, Vicky Makker, Thomas Kaley, Denison Kuruvilla, Matthew Gribbin, Jennifer McDevitt, Dominic W. Lai, Mohammed Dar
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2749–2757.
https://doi.org/10.1158/1078-0432.CCR-17-1775
Published: 14 June 2018
View article titled, Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
Open the PDF for Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors in another window
Includes: Supplementary data